Exclusive: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Institutional Investors Sentiment Index Flat in Q2 2016

November 28, 2016 - By Hazel Jackson   ·   0 Comments

Exclusive: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Institutional Investors Sentiment Index Flat in  Q2 2016

Sentiment for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) institutional sentiment decreased to 0.96 in Q2 2016. Its down -0.23, from 1.19 in 2016Q1. The ratio turned negative, as 243 hedge funds increased or started new holdings, while 205 cut down and sold their positions in Regeneron Pharmaceuticals Inc. The hedge funds in our partner’s database now have: 70.88 million shares, down from 78.30 million shares in 2016Q1. Also, the number of hedge funds holding Regeneron Pharmaceuticals Inc in their top 10 holdings increased from 9 to 10 for an increase of 1. Sold All: 51 Reduced: 154 Increased: 193 New Position: 50.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has a market cap of $41.55 billion. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It has a 58 P/E ratio. It commercializes medicines for eye diseases, high low-density lipoprotein cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases.

The stock decreased 1.06% or $4.25 on November 25, hitting $398.16. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has declined 2.15% since April 25, 2016 and is downtrending. It has underperformed by 8.17% the S&P500.

Analysts await Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report earnings on February, 14. They expect $2.51 EPS, up 71.92% or $1.05 from last year’s $1.46 per share. REGN’s profit will be $261.93M for 39.66 P/E if the $2.51 EPS becomes a reality. After $2.41 actual EPS reported by Regeneron Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 4.15% EPS growth.

According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)”

Lagoda Investment Management L.P. holds 9.47% of its portfolio in Regeneron Pharmaceuticals Inc for 72,738 shares. Polen Capital Management Llc owns 787,870 shares or 3.49% of their US portfolio. Moreover, Premier Asset Managment Llc has 3.3% invested in the company for 36,575 shares. The Texas-based Ray Gerald L & Associates Ltd has invested 3.25% in the stock. Ithaka Group Llc, a Maryland-based fund reported 63,393 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 1 buying transaction, and 3 selling transactions for $20.83 million net activity.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage

Ratings analysis reveals 47% of Regeneron Pharmaceuticals Inc.’s analysts are positive. Out of 19 Wall Street analysts rating Regeneron Pharmaceuticals Inc., 9 give it “Buy”, 1 “Sell” rating, while 9 recommend “Hold”. The lowest target is $300 while the high is $700. The stock’s average target of $562.67 is 41.32% above today’s ($398.16) share price. REGN was included in 41 notes of analysts from July 28, 2015. The rating was maintained by Bernstein on Wednesday, August 5 with “Outperform”. The firm has “Equal-Weight” rating given on Friday, October 2 by Morgan Stanley. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Outperform” rating by Wells Fargo on Friday, December 4. Credit Suisse initiated Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Wednesday, January 20 with “Neutral” rating. RBC Capital Markets maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Monday, August 31 with “Buy” rating. The firm has “Buy” rating given on Monday, September 7 by UBS. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Buy” rating given on Tuesday, March 15 by Gabelli. The company was maintained on Wednesday, August 5 by RBC Capital Markets. Chardan Capital Markets downgraded the stock to “Sell” rating in Monday, January 25 report. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Buy” rating given on Monday, April 4 by Roth Capital.

REGN Company Profile

Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. The Firm has over 10 product candidates in clinical development. These consist of Trap clinical programs and over 10 human monoclonal antibody product candidates. The Firm has generated each of the antibodies using its VelocImmune technology. The Company’s ARCALYST (rilonacept) Injection for subcutaneous Use is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children over 12 year.

More important recent Regeneron Pharmaceuticals Inc (NASDAQ:REGN) news were published by: Fool.com which released: “Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis” on November 18, 2016, also Fool.com published article titled: “Regeneron Pharmaceuticals, Inc. Dropped 14.3% in October — Here’s Why”, Investorplace.com published: “Buy Regeneron Pharmaceuticals Inc (REGN) Now, Don’t Fold” on November 18, 2016. More interesting news about Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was released by: Forbes.com and their article: “Regeneron Pharmaceuticals Becomes Oversold (REGN)” with publication date: October 31, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>